摘要
Abstract
Objective To investigate the effects of nimotuzumab combined with irinotecan on colon cancer cells. Methods Colon cancer SW480 cells were treated with nimotuzumab, irinotecan or nimotuzumab combined with irinotecan for 24h and 48h, respectively. Growth inhibition rate of SW480 cells were measured by MTT assay, apoptosis was detected by flow cytometery, the expressive levels of ERK1/2, pERK1/2 and BRCA1 were detected by Western blot. Results The growth inhibition rate and apoptosis rate of colon cancer SW480 cells treated by nimotuzumab combined with irinotecan for 48h were significantly higher with those of other groups(both P<0.01 ). There were no changes in ERK1/2 expression in all groups and no changes in pERK1/2 expression in control and irinotecan groups, however, pRK1/2 was decreased in nimotuzumab group and nimotuzumab combined with irinotecan group. The expressive levels of BRCA1 were elevated in nimotuzumab and irinotecan groups, but were decreased in nimotuzumab combined with irinotecan group. Conclusion Nimotuzumab enhances the sensitivity of colon cancer cells to irinotecan treatment, which may be associated with the down-regulation of BRCA1 expression in colon cancer cells.关键词
大肠癌/尼妥珠单抗/伊立替康/乳腺癌易感基因1Key words
Colon cancer/ Nimotuzumab/ Irinotecan/ BRCA1
